Skip to content

Dr. Shelley Boyd


Dr. Boyd is founding President and CEO of Tracery Ophthalmics and founding President and CSO of Translatum Medicus. As a clinician-scientist at St Michael’s Hospital, she oversees the Walter Retinal Research Laboratory. Shelley was formerly head of the Ocular Angiogenesis Research Program for Novartis during the diligence, in-licensing and early development of Lucentis® with Genentech, USA for “wet” age-related macular degeneration (AMD). Shelley now uniquely aligns her knowledge of science, medicine and the pharmaceutical industry to tackle the unmet need of “dry” AMD. She is founding Director of the High Risk Dry AMD Clinic, the first of its kind in Canada, where Tracery’s novel, functional imaging method is applied, generating new image-based biomarkers. Her work with Tracery awarded her Johnson & Johnson’s Artificial Intelligence for Drug Discovery top prize, the Southern Ontario Smart Computing for Innovation Program award as well as IBM’s I3 award.